Xilio Therapeutics Inc (XLO)
Xilio Therapeutics Inc is a clinical-stage biotechnology company listed on NASDAQ under the ticker XLO. The company focuses on discovering and developing masked immuno-oncology therapies designed to target cancer while limiting activity in healthy tissue. Its pipeline includes XTX501, a bispecific PD-1 / masked IL-2 candidate being evaluated for metastatic non-small cell lung cancer; Efarindodekin alfa, a masked IL-12 program in Phase 2 testing for advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XLO
|
—
|
—
|
—
|
$20
|
129.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-1.7x
|
0.7x
|
1.0x
|
51.273 M
|
-91.614 M
|
11.5%
|
62.7%
|
-1.7
|
—
|
183.3%
|
